(13S,17R)-11-[4-(dimethylamino)phenyl]-13-methyl-3'-methylidenespiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (13S,17R)-11-[4-(dimethylamino)phenyl]-13-methyl-3'-methylidenespiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one
• 化学式: C₃₀H₃₇NO₂
• 分子量: 443.6
• InChiKey: OSJVPODVYMUXNH-POEANNJPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  33
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING PROGESTERONE-DEPENDENT CONDITIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR TRAITER DES ÉTATS DÉPENDANTS DE LA PROGESTÉRONE
  申请人：REPROS THERAPEUTICS INC

  公开号：WO2009134725A2

  公开（公告）日：2009-11-05

  The subject matter of the instant invention is pertinent to the field of treatment of progesterone-dependent conditions. Compositions for practicing the methods, comprising one or more 19-norsteroid progesterone receptor modulators having a monomethylamine-substituted phenyl ring at the 11 β-position of carbon 11 and exhibiting low antiglucocorticoid activity, are also disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation.